354 related articles for article (PubMed ID: 30592365)
1. Adrenomedullin in heart failure: pathophysiology and therapeutic application.
Voors AA; Kremer D; Geven C; Ter Maaten JM; Struck J; Bergmann A; Pickkers P; Metra M; Mebazaa A; Düngen HD; Butler J
Eur J Heart Fail; 2019 Feb; 21(2):163-171. PubMed ID: 30592365
[TBL] [Abstract][Full Text] [Related]
2. Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.
Ter Maaten JM; Kremer D; Demissei BG; Struck J; Bergmann A; Anker SD; Ng LL; Dickstein K; Metra M; Samani NJ; Romaine SPR; Cleland J; Girerd N; Lang CC; van Veldhuisen DJ; Voors AA
Eur J Heart Fail; 2019 Jun; 21(6):732-743. PubMed ID: 30843353
[TBL] [Abstract][Full Text] [Related]
3. Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis.
Geven C; Kox M; Pickkers P
Front Immunol; 2018; 9():292. PubMed ID: 29520277
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2).
Geven C; Blet A; Kox M; Hartmann O; Scigalla P; Zimmermann J; Marx G; Laterre PF; Mebazaa A; Pickkers P
BMJ Open; 2019 Feb; 9(2):e024475. PubMed ID: 30782906
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects.
Geven C; van Lier D; Blet A; Peelen R; Ten Elzen B; Mebazaa A; Kox M; Pickkers P
Br J Clin Pharmacol; 2018 Sep; 84(9):2129-2141. PubMed ID: 29856470
[TBL] [Abstract][Full Text] [Related]
6. Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis.
Geven C; Bergmann A; Kox M; Pickkers P
Shock; 2018 Aug; 50(2):132-140. PubMed ID: 29324626
[TBL] [Abstract][Full Text] [Related]
7. Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis.
Deniau B; Takagi K; Asakage A; Mebazaa A
Expert Opin Investig Drugs; 2021 Feb; 30(2):95-102. PubMed ID: 33256482
[No Abstract] [Full Text] [Related]
8. Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates.
Geven C; Kox M; Blet A; Mebazaa A; Schroedter M; Struck J; Bergmann A; Pickkers P
Toxicol Appl Pharmacol; 2019 Apr; 369():1-16. PubMed ID: 30822437
[TBL] [Abstract][Full Text] [Related]
9. Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101).
Karakas M; Jarczak D; Becker M; Roedl K; Addo MM; Hein F; Bergmann A; Zimmermann J; Simon TP; Marx G; Lütgehetmann M; Nierhaus A; Kluge S
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32796765
[TBL] [Abstract][Full Text] [Related]
10. Bioactive adrenomedullin for assessment of venous congestion in heart failure.
Egerstedt A; Czuba T; Bronton K; Lejonberg C; Ruge T; Wessman T; Rådegran G; Schulte J; Hartmann O; Melander O; Smith JG
ESC Heart Fail; 2022 Oct; 9(5):3543-3555. PubMed ID: 35903845
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.
Pandhi P; Ter Maaten JM; Emmens JE; Struck J; Bergmann A; Cleland JG; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Cotter G; Davison B; van Veldhuisen DJ; Voors AA
Eur J Heart Fail; 2020 Apr; 22(4):683-691. PubMed ID: 31797505
[TBL] [Abstract][Full Text] [Related]
12. Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock:
van Lier D; Picod A; Marx G; Laterre PF; Hartmann O; Knothe C; Azibani F; Struck J; Santos K; Zimmerman J; Bergmann A; Mebazaa A; Pickkers P
Front Med (Lausanne); 2022; 9():1058235. PubMed ID: 36530868
[TBL] [Abstract][Full Text] [Related]
13. Bioactive adrenomedullin a prognostic biomarker in patients with mild to moderate dyspnea at the emergency department: an observational study.
Bronton K; Wessman T; Gränsbo K; Schulte J; Hartmann O; Melander O
Intern Emerg Med; 2022 Mar; 17(2):541-550. PubMed ID: 34173962
[TBL] [Abstract][Full Text] [Related]
14. Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis.
Geven C; Peters E; Schroedter M; Struck J; Bergmann A; McCook O; Radermacher P; Kox M; Pickkers P
Shock; 2018 Dec; 50(6):648-654. PubMed ID: 29324627
[TBL] [Abstract][Full Text] [Related]
15. Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis.
Caironi P; Latini R; Struck J; Hartmann O; Bergmann A; Maggio G; Cavana M; Tognoni G; Pesenti A; Gattinoni L; Masson S;
Chest; 2017 Aug; 152(2):312-320. PubMed ID: 28411114
[TBL] [Abstract][Full Text] [Related]
16. Effects of the Non-Neutralizing Humanized Monoclonal Anti-Adrenomedullin Antibody Adrecizumab on Hemodynamic and Renal Injury in a Porcine Two-Hit Model.
Thiele C; Simon TP; Szymanski J; Daniel C; Golias C; Hartmann O; Struck J; Martin L; Marx G; Schuerholz T
Shock; 2020 Dec; 54(6):810-818. PubMed ID: 32554994
[TBL] [Abstract][Full Text] [Related]
17. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study.
Mebazaa A; Geven C; Hollinger A; Wittebole X; Chousterman BG; Blet A; Gayat E; Hartmann O; Scigalla P; Struck J; Bergmann A; Antonelli M; Beishuizen A; Constantin JM; Damoisel C; Deye N; Di Somma S; Dugernier T; François B; Gaudry S; Huberlant V; Lascarrou JB; Marx G; Mercier E; Oueslati H; Pickkers P; Sonneville R; Legrand M; Laterre PF;
Crit Care; 2018 Dec; 22(1):354. PubMed ID: 30583748
[TBL] [Abstract][Full Text] [Related]
18. Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.
Arfsten H; Goliasch G; Bartko PE; Prausmüller S; Spinka G; Cho A; Novak J; Haslacher H; Strunk G; Struck J; Hülsmann M; Pavo N
Br J Clin Pharmacol; 2021 Mar; 87(3):916-924. PubMed ID: 32598074
[TBL] [Abstract][Full Text] [Related]
19. Bioactive adrenomedullin as a marker of congestion and disease progression in patients with a systemic right ventricle.
Ansari Ramandi MM; Hendriks PM; Voors AA; van den Bosch AE; van Melle JP
Int J Cardiol; 2024 Aug; 408():132107. PubMed ID: 38685456
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.
Laterre PF; Pickkers P; Marx G; Wittebole X; Meziani F; Dugernier T; Huberlant V; Schuerholz T; François B; Lascarrou JB; Beishuizen A; Oueslati H; Contou D; Hoiting O; Lacherade JC; Chousterman B; Pottecher J; Bauer M; Godet T; Karakas M; Helms J; Bergmann A; Zimmermann J; Richter K; Hartmann O; Pars M; Mebazaa A;
Intensive Care Med; 2021 Nov; 47(11):1284-1294. PubMed ID: 34605947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
